tiprankstipranks
pc:timbe

Timberlyne Therapeutics

San Diego, California, United States
timberlyne-tx.com
Timberlyne Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for autoimmune disorders. The company is advancing CM313, a monoclonal antibody targeting CD38, aimed at addressing diseases with high unmet medical needs. Formed through a partnership between Mountainfield Venture Partners and Keymed Biosciences, Timberlyne Therapeutics holds global development and commercial rights for CM313 outside of greater China.

Leadership & Board

Key Executives
Co-FounderChristian Fougner
Current Number of Employees8
Current LinkedIn Followers2,991

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$180M
Total Amount Raised$180M
Total Funding Rounds1
Total Funding Rounds1
Latest Funding Amount$180M
Latest Funding Amount$180M
Latest Funding RoundSeries A
Latest Funding RoundSeries A
Post-Money Valuation
Post-Money Valuation

Employee Trend

Timberlyne Therapeutics had 8 employees as of April 6, 2026. The number of employees decreased by 1 (11.11%) week-over-week.
8Latest Employee Count
1(-11.11%)Week-Over-Week Change
Employee Trend serves as a data-driven indicator of company growth and expansion. The measurement reflects how a company’s workforce size changes over time.

Social Trend

Timberlyne Therapeutics had 2,991 followers as of April 6, 2026. The number of followers increased by 7 (0.23%) week-over-week.
2,991Latest Followers Count
7(0.23%)Week-Over-Week Change
LinkedIn Follower Trend serves as a data-driven indicator of market interest and company visibility. The measurement reflects how a company’s LinkedIn follower count changes over time.

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Jan 10, 2025
Series A
$180.00M

Investors

Related News and Analysis